Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China

被引：0
作者：
Sui, Weiwei [1 ,2 ]
An, Gang [3 ]
Deng, Shuhui [4 ,5 ]
Xu, Yan [4 ,5 ]
Hao, Mu [6 ,7 ]
Fu Mingwei [6 ,7 ]
Wang, Tingyu [6 ,7 ]
Yi, Shuhua [4 ,5 ]
Zhao, Yaozhong [8 ,9 ,10 ]
Zou, Dehui [4 ,5 ]
Li, Zengjun [11 ]
Qiu, Lugui [6 ,7 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Lymphoma & Myeloma Ctr, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Lymphoma & Myeloma Ctr, State Key Lab Expt Hematol, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[5] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[7] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[8] Chinese Acad Med Sci, Hematol Blood Dis Hosp, Tianji, Tianjing, Peoples R China
[9] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[10] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
来源：
BLOOD | 2019年 / 134卷
关键词：
Real-world; Ixazomib; multiple myeloma;
D O I：
10.1182/blood-2019-126718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5581
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries
    Abildgaard, Niels
    Anttila, Pekka
    Waage, Anders
    Rubin, Katrine Hass
    Orstavik, Sigurd
    Bent-Ennakhil, Nawal
    Ma, Yuanjun
    Freilich, Jonatan
    Hansson, Markus
    EUROPEAN JOURNAL OF CANCER, 2024, 201
  • [42] Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs
    Hari, Parameswaran
    Ung, Brian
    Abouzaid, Safiya
    Agarwal, Amit
    Parikh, Kejal
    FUTURE ONCOLOGY, 2019, 15 (35) : 4045 - 4056
  • [43] Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment
    Jennings, Luke
    Gajra, Ajeet
    Balijevic, Muhamed
    Smith, Yolaine
    Feinberg, Bruce
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S425 - S426
  • [44] Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China
    Bao, Li
    Liu, Ai-Jun
    Chu, Bin
    Wang, Qian
    Dong, Yu-Jun
    Lu, Min-Qiu
    Shi, Lei
    Gao, Shan
    Wang, Yu-Tong
    Wang, Li-Fang
    Chen, Wen-Ming
    Zhuang, Jun-Ling
    CANCER MEDICINE, 2023, 12 (03): : 3101 - 3111
  • [45] Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
    Bakirtas, Mehmet
    Dal, Mehmet Sinan
    Yigenoglu, Tugce Nur
    Giden, Asli Odabasi
    Serin, Istemi
    Basci, Semih
    Kalpakci, Yasin
    Korkmaz, Serdal
    Ekinci, Omer
    Albayrak, Murat
    Basturk, Abdulkadir
    Ozatli, Duzgun
    Dogu, Mehmet Hilmi
    Hacibekiroglu, Tuba
    Cakar, Merih Kizil
    Ulas, Turgay
    Miskioglu, Mine
    Gulturk, Emine
    Eser, Bulent
    Altuntas, Fevzi
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (06) : 563 - 569
  • [46] The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
    Nakayama, Hitomi
    Aisa, Yoshinobu
    Ito, Chisako
    Sakurai, Aki
    Nakazato, Tomonori
    HEMATOLOGY REPORTS, 2024, 16 (04) : 593 - 602
  • [47] Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting
    Bonello, Francesca
    Cani, Lorenzo
    D'Agostino, Mattia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
    Nakaya, Aya
    Shibayama, Hirohiko
    Uoshima, Nobuhiko
    Yamamura, Ryosuke
    Yoshioka, Satoshi
    Imada, Kazunori
    Shimura, Yuji
    Hotta, Masaaki
    Matsui, Toshimitsu
    Kosugi, Satoru
    Hanamoto, Hitoshi
    Uchiyama, Hitoji
    Yoshihara, Satoshi
    Fuchida, Shin-ichi
    Onda, Yoshiyuki
    Tanaka, Yasuhiro
    Ohta, Kensuke
    Matsuda, Mitsuhiro
    Kanda, Junya
    Yoko, Adachi
    Kiyota, Miki
    Kawata, Eri
    Takahashi, Ryoichi
    Fukushima, Kentaro
    Tanaka, Hirokazu
    Yagi, Hideo
    Takakuwa, Teruhito
    Hosen, Naoki
    Ito, Tomoki
    Shimazaki, Chihiro
    Takaori-Kondo, Akifumi
    Kuroda, Junya
    Matsumura, Itaru
    Hino, Masayuki
    LEUKEMIA RESEARCH REPORTS, 2023, 20
  • [49] Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
    Varga, Gergely
    Nagy, Zsolt
    Demeter, Judit
    Kosztolanyi, Szabolcs
    Szomor, Arpad
    Alizadeh, Hussain
    Deak, Beata
    Schneider, Tamas
    Plander, Mark
    Szendrei, Tamas
    Varoczy, Laszlo
    Illes, Arpad
    Batai, Arpad
    Peto, Monika
    Mikala, Gabor
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (04) : 1615 - 1620
  • [50] Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma
    Salvini, Marco
    Troia, Rossella
    Giudice, Davide
    Pautasso, Chiara
    Boccadoro, Mario
    Larocca, Alessandra
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (01) : 91 - 99
12345